Product Description
Bosnalijek D.D is developing Tridecactide as a treatment for Relapsing-Remitting Multiple Sclerosis. (Sourced from: https://clinicaltrials.gov/study/NCT03283397)
Mechanisms of Action: OPRD Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bosnia
Approved Indications: None
Known Adverse Events: None
Company: Bosnalijek D.D
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Sclerosis, Relapsing-Remitting
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RAP-CS-01 | P3 |
Terminated |
Multiple Sclerosis, Relapsing-Remitting |
2023-07-01 |